Brokerages Expect Vapotherm Inc (VAPO) to Post ($0.82) EPS
Shares of Vapotherm Inc (NYSE:VAPO) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus price objective of $25.50 for the company and are anticipating that the company will post ($0.82) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Vapotherm an industry rank of 99 out of 256 based on the ratings given to related companies.
A number of analysts recently commented on VAPO shares. Canaccord Genuity lifted their price objective on Vapotherm from $22.00 to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, March 13th. Zacks Investment Research lowered Vapotherm from a “hold” rating to a “sell” rating in a report on Saturday, March 16th.
Shares of NYSE:VAPO traded down $0.10 during midday trading on Wednesday, hitting $16.25. 425 shares of the stock were exchanged, compared to its average volume of 41,242. The company has a market capitalization of $282.54 million and a PE ratio of -1.17. The company has a quick ratio of 4.84, a current ratio of 6.35 and a debt-to-equity ratio of 1.01. Vapotherm has a twelve month low of $14.70 and a twelve month high of $22.29.
Vapotherm (NYSE:VAPO) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.03. The firm had revenue of $12.30 million for the quarter, compared to analyst estimates of $11.90 million. As a group, equities analysts anticipate that Vapotherm will post -3.15 earnings per share for the current year.
Vapotherm Company Profile
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
Further Reading: Dead Cat Bounce
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.